Gracell Biotechnologies Receives IND Clearance For Phase 1 Trial Of GC012F In Multiple Myeloma

Gracell Biotechnologies Inc. (GRCL) announced the FDA has cleared Investigational New Drug application, allowing the company to initiate a Phase 1 clinical trial of GC012F in the United States for the early-line treatment of multiple myeloma.

Related Keywords

Amsterdam ,Noord Holland ,Netherlands ,China ,Hong Kong ,Dutch ,Chinese , ,Utz Quality Foods ,China Evergrande Group ,Philips Electronics ,Drug Administration ,Quality Foods ,Original Potato Chips ,Fda ,Gracell Biotechnologies ,